Table 1. Summary of final study design.
Baseline | Weeks 1–2 | 2 week visit | Weeks 3–4 | 4 week visit |
---|---|---|---|---|
Clinical evaluation;
randomize |
Placebo
2.5mg 5mg |
Clinical evaluation; ↑
dopaminometic, if indicated |
Placebo
2.5mg 5mg |
Clinical evaluation; return to
routine clinical care |
This table summarizes the study design and timing of assessments and interventions for the last 19 subjects enrolled in the study. ↑ dopaminometic: dose increase allowed for antiparkinsonian medication, if parkinsonism had worsened since starting the study. See Methods and Figure 1 for further details.